Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Infectious DiseaseRespiratory

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1793922

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1793922

Upper Respiratory Tract Infection Treatment

PUBLISHED:
PAGES: 372 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5850
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Upper Respiratory Tract Infection Treatment Market to Reach US$14.9 Billion by 2030

The global market for Upper Respiratory Tract Infection Treatment estimated at US$12.8 Billion in the year 2024, is expected to reach US$14.9 Billion by 2030, growing at a CAGR of 2.6% over the analysis period 2024-2030. Antibiotics, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$8.2 Billion by the end of the analysis period. Growth in the NSAIDs & Nasal Decongestants segment is estimated at 1.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.5 Billion While China is Forecast to Grow at 5.2% CAGR

The Upper Respiratory Tract Infection Treatment market in the U.S. is estimated at US$3.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.9 Billion by the year 2030 trailing a CAGR of 5.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.9% and 2.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.4% CAGR.

Global Upper Respiratory Tract Infection Treatment Market - Key Trends & Drivers Summarized

Why Does the Treatment of Upper Respiratory Tract Infections Remain a Public Health Priority?

Upper respiratory tract infections (URTIs), which include ailments such as the common cold, pharyngitis, sinusitis, laryngitis, and tonsillitis, continue to be among the most widespread health issues globally, affecting individuals across all age groups. These infections are primarily viral in origin, though bacterial agents also contribute to a significant portion of cases, particularly in more severe or prolonged episodes. Despite being self-limiting in many instances, URTIs represent a major public health concern due to their high incidence rate, economic burden, and potential to cause complications if inadequately managed. The ease of transmission, especially in densely populated settings like schools, workplaces, and public transportation, ensures their constant presence throughout the year, with seasonal peaks in colder months. From a treatment perspective, URTIs account for a large volume of outpatient visits and over-the-counter medication purchases globally. Additionally, they are one of the leading causes of unnecessary antibiotic prescriptions, contributing to the growing challenge of antimicrobial resistance. Public health authorities and healthcare providers are increasingly focused on balancing effective symptom relief with judicious use of pharmacological therapies. This has led to a surge in demand for targeted, evidence-based treatment options that alleviate discomfort, reduce infection duration, and minimize the risk of overmedication. As a result, treatment of URTIs remains a critical area of focus for healthcare systems, pharmaceutical developers, and global health organizations.

How Are Evolving Treatment Modalities and Drug Innovations Reshaping URTI Management?

The landscape of upper respiratory tract infection treatment is evolving with the introduction of innovative drugs, improved delivery mechanisms, and a greater emphasis on evidence-based therapeutic strategies. While symptomatic relief through decongestants, antipyretics, antihistamines, and cough suppressants remains the cornerstone of URTI management, there is increasing interest in combination therapies that address multiple symptoms simultaneously to enhance patient comfort and compliance. The development of advanced formulations, such as extended-release tablets, nasal sprays, and lozenges with localized action, is improving the speed and effectiveness of symptom control. In cases involving bacterial infections, narrow-spectrum antibiotics are being promoted over broad-spectrum alternatives to reduce the risk of resistance. At the same time, novel antiviral agents are being explored to treat specific viral strains more effectively, particularly in immunocompromised populations and in cases of viral pharyngitis or severe cold symptoms. The rise of personalized medicine and pharmacogenomics is also opening the door to treatments tailored to individual genetic profiles and immune responses. In parallel, non-pharmacological options such as saline irrigation, herbal extracts, and immune-boosting nutraceuticals are gaining popularity as complementary treatments. These trends are contributing to a more holistic and patient-centered approach to URTI care, where therapeutic innovation focuses not just on rapid recovery but also on minimizing side effects and promoting long-term respiratory health.

What Role Do Demographics, Seasonality, and Healthcare Infrastructure Play in Treatment Demand?

The demand for upper respiratory tract infection treatment is closely linked to demographic profiles, seasonal patterns, and the capacity of healthcare systems to deliver timely care. Children and the elderly represent the most vulnerable groups due to their comparatively weaker or less-developed immune systems, leading to higher incidence rates and a greater likelihood of complications. Pediatric URTI cases, in particular, drive significant volumes of clinical consultations and medication use, as parents seek fast and effective remedies to reduce school absenteeism and discomfort. Similarly, elderly populations with comorbid conditions are often at greater risk of secondary infections or hospitalization, requiring more careful treatment strategies. Seasonality is another major factor, with sharp increases in cases during colder months or rainy seasons when viruses spread more rapidly due to indoor crowding and reduced air circulation. Geographic differences in climate, population density, and pollution levels also influence infection rates and treatment approaches. Healthcare infrastructure plays a decisive role in the accessibility and quality of treatment, with well-equipped systems providing rapid diagnostics, access to appropriate medications, and effective public health messaging. In contrast, underserved regions may face delays in diagnosis and treatment, leading to prolonged illness or overreliance on over-the-counter solutions. The integration of telemedicine and digital health platforms is also influencing how URTIs are managed, particularly in urban centers, by enabling faster consultations, digital prescriptions, and follow-ups without the need for physical clinic visits. These demographic and structural factors collectively shape the scale, urgency, and mode of upper respiratory infection treatment across different regions.

What Are the Key Factors Driving Growth in the Upper Respiratory Tract Infection Treatment Market?

The growth in the upper respiratory tract infection treatment market is driven by a combination of epidemiological trends, consumer behavior, and healthcare innovation. One of the foremost drivers is the consistently high global incidence of URTIs, which ensures a stable and recurring demand for both prescription and over-the-counter therapies. The widespread nature of these infections means that even modest improvements in treatment effectiveness or accessibility can translate into significant market gains. Another key factor is the increasing consumer preference for rapid relief and multi-symptom formulations, which has led to the development of more advanced combination drugs and delivery formats. The expansion of retail pharmacy chains, e-commerce drug platforms, and telehealth services is also making it easier for consumers to access treatment without visiting a hospital or clinic. Rising awareness about the risks of antibiotic misuse is encouraging both patients and providers to adopt more responsible treatment practices, which is fueling interest in alternative and supportive therapies, including herbal and homeopathic options. Additionally, the growth of health insurance coverage in emerging economies is improving affordability and access to branded medications. Pharmaceutical companies are investing in targeted R&D to differentiate their URTI portfolios, focusing on pediatric-specific formulations, new antivirals, and better drug tolerability. Public health campaigns aimed at respiratory hygiene and early symptom management are further contributing to a proactive approach to care. These converging forces are creating a robust and evolving market for upper respiratory tract infection treatment that spans all age groups and healthcare systems, ensuring ongoing innovation and expansion in the years ahead.

SCOPE OF STUDY:

The report analyzes the Upper Respiratory Tract Infection Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Antibiotics, NSAIDs & Nasal Decongestants, Other Treatments); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); Indication (Common Cold, Sinusitis, Pharyngitis, Laryngitis)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Chiesi Farmaceutici S.p.A.
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mylan (Viatris)
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Roche Holding AG
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Verona Pharma plc

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP38286

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Upper Respiratory Tract Infection Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Viral Infections Throws the Spotlight on Rapid-Relief URTI Treatment Options
    • Post-Pandemic Awareness Spurs Demand for Early Symptom Management and Preventive Therapies
    • Here's How Growth in Self-Medication Is Driving Adoption of OTC and Herbal Remedies for URTIs
    • Antibiotic Stewardship Campaigns Strengthen the Business Case for Non-Antibiotic Treatment Alternatives
    • Increasing Preference for Symptom-Specific Combination Therapies Propels Innovation in Formulation Design
    • Telemedicine and E-Pharmacy Expansion Accelerate Access to Prescription and OTC URTI Treatments
    • Here's the Story: How Seasonal Peaks and Viral Mutation Cycles Are Reshaping Inventory and Demand Patterns
    • Growing Geriatric and Pediatric Populations Expand the Addressable Market for Age-Appropriate Treatments
    • Consumer Shift Toward Immune-Boosting Products Sustains Growth in Supplements Targeting URTI Prevention
    • Technological Advancements in Rapid Diagnostics Drive Timely and Targeted Treatment Decisions
    • Urbanization and Air Pollution Levels Generate Demand for Respiratory Relief Medications and Protectives
    • Rising Healthcare Access in Developing Regions Fuels Market Penetration of Generic URTI Therapeutics
    • Cross-Border E-Commerce Trends Drive Global Reach of OTC and Natural URTI Remedies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Upper Respiratory Tract Infection Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Upper Respiratory Tract Infection Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for NSAIDs & Nasal Decongestants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for NSAIDs & Nasal Decongestants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for NSAIDs & Nasal Decongestants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Laryngitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Laryngitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Laryngitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Common Cold by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Common Cold by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Common Cold by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Sinusitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Sinusitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Sinusitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Pharyngitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Pharyngitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Pharyngitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Upper Respiratory Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • JAPAN
    • Upper Respiratory Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • CHINA
    • Upper Respiratory Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: China 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: China 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: China 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • EUROPE
    • Upper Respiratory Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Upper Respiratory Tract Infection Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • FRANCE
    • Upper Respiratory Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: France 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: France 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: France 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • GERMANY
    • Upper Respiratory Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Upper Respiratory Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Upper Respiratory Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Upper Respiratory Tract Infection Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Upper Respiratory Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • INDIA
    • Upper Respiratory Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 167: India Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: India 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: India 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: India 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Upper Respiratory Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Upper Respiratory Tract Infection Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Upper Respiratory Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Upper Respiratory Tract Infection Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • AFRICA
    • Upper Respiratory Tract Infection Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Upper Respiratory Tract Infection Treatment by Type - Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Type - Percentage Breakdown of Value Sales for Antibiotics, NSAIDs & Nasal Decongestants and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Upper Respiratory Tract Infection Treatment by Indication - Laryngitis, Common Cold, Sinusitis and Pharyngitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Indication - Percentage Breakdown of Value Sales for Laryngitis, Common Cold, Sinusitis and Pharyngitis for the Years 2014, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Upper Respiratory Tract Infection Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Upper Respiratory Tract Infection Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!